2023
DOI: 10.1016/j.intimp.2023.109777
|View full text |Cite
|
Sign up to set email alerts
|

Serum exosomal miR-146a-3p associates with disease severity and efficacy of sublingual immunotherapy in allergic rhinitis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
0
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 40 publications
0
0
0
Order By: Relevance
“…78 In addition, it was found that serum exosome-derived mi-146a-3p could predict the short-and long-term efficacy of SLIT in AR patients. 79 These studies suggest that miRNAs may play an important regulatory role in immunotherapy of AR. This also suggests that ncRNAs will play an increasingly important role in AR immunotherapy in the future and will provide better ideas for the treatment of AR.…”
Section: Ncrna and Ar Immunotherapymentioning
confidence: 98%
See 1 more Smart Citation
“…78 In addition, it was found that serum exosome-derived mi-146a-3p could predict the short-and long-term efficacy of SLIT in AR patients. 79 These studies suggest that miRNAs may play an important regulatory role in immunotherapy of AR. This also suggests that ncRNAs will play an increasingly important role in AR immunotherapy in the future and will provide better ideas for the treatment of AR.…”
Section: Ncrna and Ar Immunotherapymentioning
confidence: 98%
“…A study examined the expression of 48 miRNAs in AR patients treated with SCIT and found that some proinflammatory miRNAs were significantly downregulated and several miRNAs regulating the Th1/Th2 balance were upregulated after 6 months of SCIT treatment 78 . In addition, it was found that serum exosome‐derived mi‐146a‐3p could predict the short‐ and long‐term efficacy of SLIT in AR patients 79 . These studies suggest that miRNAs may play an important regulatory role in immunotherapy of AR.…”
Section: Ncrna and Ar Immunotherapymentioning
confidence: 99%